Anixa Biosciences is trading 6.1% down at $3.08 amid a sharp broader-market sell-off, the most likely explanation for the decline. - The Nasdaq was down 5.02%, while biotech-sector XBI was down 5.19%. - No company-specific announcement explaining the November 5 drop was found. - Anixa’s latest announcement, on November 4, concerned a planned December presentation of its ovarian cancer CAR-T trial; it does not establish a direct reason for today’s decline.